Levosimendan does not reduce the mortality of critically ill adult patients with sepsis and septic shock: a meta-analysis.

ABSTRACT:

Background

Previous studies on whether or not levosimendan improved the prognosis of patients with sepsis and septic shock have been inconsistent. We aimed to provide an updated analysis of the therapeutic value of levosimendan in adult patients with sepsis and septic shock, in order to provide evidence-based medical evidence for its use.

Methods

PubMed, Embase, Cochrane Library, Wanfang Data, and CNKI were searched until August 2018 without language restriction. Randomized controlled studies of levosimendan with either inotropic drugs or placebo for the treatment of sepsis or septic shock were enrolled. The primary outcome was mortality, and cardiac index and serum lactate levels were the secondary outcomes.

Results

A total of 20 randomized controlled studies were in

SUBMITTER: Feng F 

PROVIDER: S-EPMC6511414 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature